Similarly, Wang et al.’s Phase II clinical trial showed that in patients with advanced axillary melanoma, apatinib combined with carrelizumab presented positive anti-tumor effects, and mutations in the MUC16 gene were associated with better survival outcomes in patients (160). The gene discussed is MUC16; the disease is neoplasm.